|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.46 USD | +0.60% |
|
-5.04% | +7.55% |
| 07-13 | GSK posts encouraging data for bowel cancer treatment Jemperli | AN |
| 06-29 | AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from Russell 3000E Growth Benchmark | CI |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Neutral | Bullish |
| Resistance | 58 | 70.22 | 70.1 |
| Spread/Res. | -10.10% | -25.75% | -25.62% |
| Spread/Supp. | +3.68% | +9.98% | +40.69% |
| Support | 50.29 | 47.41 | 37.06 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- ANAB Stock
- Charts AnaptysBio, Inc.
Select your edition
All financial news and data tailored to specific country editions
